Xintela starts clinical study of XSTEM® in knee osteoarthritis

Xintela starts its first-in-human study (Phase I/IIa) with XSTEM® for the treatment of knee osteoarthritis in Australia. XSTEM, which consists of allogeneic (donated) integrin alpha10beta1-selected mesenchymal stem cells, is developed and manufactured by Xintela.

Patients with moderate knee osteoarthritis (grade II-III) will receive a single injection of XSTEM into the knee joint. Three different doses will be assessed in up to 54 patients and each patient will be followed for 18 months. The primary goal is to show that XSTEM is safe, but also to look for preliminary efficacy signals, such as reduced cartilage degradation, regeneration of damaged cartilage and improved joint function. Initial safety data is expected before the end of 2022 and early efficacy data during 2023.

"We are very excited to start treating osteoarthritis patients with our promising stem cell product XSTEM. We have received approval for the clinical study in Australia and are now ready to start recruiting patients. Our earlier preclinical studies have shown that XSTEM has a regenerative effect and therefore has the potential to be a DMOAD (Disease Modifying Osteoarthritis Drug) and a breakthrough treatment for osteoarthritis", says Xintela's CEO Evy Lundgren-Åkerlund.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin alpha10beta1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is now entering a clinical development phase for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin alpha10beta1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.

Attachments

Xintela starts clinical study of XSTEM® in knee osteoarthritis